secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001200375-23-000027
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q2 loss widens to $11.5M; pivots to ECO Synthesis RNAi platform, cuts headcount 25%
--------------------------------------------------------------------------------

- Net loss of $11.5M ($0.17/share) vs $2.6M loss in Q2 2022; total rev $21.3M (ex-PAXLOVID up 46% YoY).
- Prioritizing ECO Synthesis RNAi therapeutics platform; aims for gram-scale synthesis by end-2023.
- Discontinued Biotherapeutics programs; reduced headcount ~25%; consolidated to HQ.
- Cash $92.1M as of June 30; projected runway extended to mid-2026.
- FY 2023 guidance reiterated: product rev $30-35M (ex-PAXLOVID), R&D rev $21-24M, gross margin 55-65%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037523000027/0001200375-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037523000027/cdxs-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001200375-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer